Zibotentan

Zibotentan (INN) (earlier code name ZD4054) is an anti-cancer candidate. It is an endothelin receptor antagonist.

It failed a phase III clinical trial for prostate cancer but other trials are planned. Tolerability of zibotentan plus docetaxel has been evaluated.